Accepted for/Published in: Journal of Medical Internet Research
Date Submitted: Jul 2, 2022
Open Peer Review Period: Jul 2, 2022 - Aug 27, 2022
Date Accepted: Nov 3, 2022
Date Submitted to PubMed: Nov 10, 2022
(closed for review but you can still tweet)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Mental health chatbot for young adults with depression symptoms during the COVID-19 pandemic: a single-blind, three-arm, randomized controlled trial
ABSTRACT
Background:
Depression has a high detection ratio among young adults, especially during the COVID-19 pandemic, which, however, occupies a low utilization of health services. Mental health chatbot is a novel digital technology to provide fully automated intervention for depression symptoms.
Objective:
The purpose of this study is to test the clinical effectiveness and nonclinical performance of the cognitive behavioral therapy (CBT)-based mental health chatbot (XiaoE) for young adults with depression symptoms during the COVID-19 pandemic.
Methods:
In a single-blind, three-arm, randomized controlled trial, participants manifesting depression symptoms aged 17-34 years recruited from a university in China were randomly assigned to mental health chatbot (XiaoE; n = 49), e-book (n = 49) or general chatbot (Xiaoai; n = 50), in a ratio of 1:1:1. The primary outcome was the reduction of depression symptoms according to the 9-item Patient Health Questionnaire (PHQ-9) at 1 week later (T1) and 1 month later (T2). Both intention-to-treat analyses and per-protocol analyses were conducted under analysis of covariance (ANCOVA) models adjusting for baseline data. Controlled multiple imputation and δ-based sensitivity analysis were performed for missing data. The secondary outcome was the level of working alliance measured using Working Alliance Questionnaire (WAQ), usability measured using the Usability Metric for User Experience-LITE (UMUX-LITE) and acceptability measured using Acceptability Scale (AS).
Results:
Intent-to-treat analysis revealed a moderate short-term effect of group diversity on the reduction of depression symptoms (PHQ-9) at T1 (F2, 136 = 17.011, P < .001, d = 0.51), while a light long-term effect at T2 (F2, 136 = 5.477, P= .005, d = 0.31). Better working alliance (WAQ, F2, 145 = 3.407, P = .036) and acceptability (AS, F2, 145 = 4.322, P = .015) was discovered with XiaoE, while no significant difference among arms was found on usability (UMUX-LITE, F2, 145 = 0.968, P = .382).
Conclusions:
This novel intervention conducting CBT provides a feasible and engaging digital therapeutic that allows easy accessibility and self-guided mental health assistance for young adults with depression symptoms. A systematic evaluation of nonclinical metrics for mental health chatbot is established in this study. In the future, concern with both clinical outcomes and nonclinical metrics is necessary to explore the mechanism by which the mental health chatbots work on patients. Further evidence is required to confirm the long-term effectiveness via trails replicated with a longer dose as well as exploration on its stronger efficacy in comparison with other active controls. Clinical Trial: Chinese Clinical Trial Registry ChiCTR2100052532; http://www.chictr.org.cn/showproj.aspx?proj=135744.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.